SPRB Stock Forecast & Price Target

Spruce Biosciences Inc. is demonstrating a promising trajectory with its product pipeline, particularly through the encouraging results of Tildacerfont, which showed larger reductions in A4 levels at higher BID doses and was well-tolerated across various dosage regimens without severe adverse events. Financially, the company is forecasted to narrow its net loss per share from $0.90 in 2024 to $0.61 in 2025, indicating a potential path toward improved fiscal health. Additionally, the moderate collaboration revenue of approximately $0.6 million, as a result of the partnership with Kaken Pharmaceutical, reflects ongoing recognition of initial payments that contribute positively to the company's financial stability.

Spruce Biosciences Inc reported a net loss of $0.21 per share for 3Q24, which, while slightly better than the forecasted loss, was primarily influenced by lower-than-expected research and development expenditures. The company faces significant risks, including the inability to redirect its strategy following the clinical failure of tildacerfont, potential long-term dilution, and challenges in achieving clinical and regulatory milestones amidst increasing competition. With the recent disappointing clinical readouts for tildacerfont, Spruce's prospects appear bleak as it enters a holding pattern, further compounding concerns about the viability of its pipeline and the company's future performance.